Fosphenytoin

Fosphenytoin
Clinical data
Trade namesCerebyx, Pro-Epanutin
AHFS/Drugs.comMonograph
MedlinePlusa604036
License data
Routes of
administration
Intravenous, intramuscular
ATC code
Legal status
Legal status
  • US: WARNING[1]Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability100% (IM)
Protein binding95–99%
MetabolismLiver
Elimination half-life15 minutes to convert to phenytoin
ExcretionKidney (as phenytoin)
Identifiers
  • (2,5-Dioxo-4,4-diphenyl-imidazolidin-1-yl)methoxyphosphonic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H15N2O6P
Molar mass362.278 g·mol−1
3D model (JSmol)
  • O=C3N(C(=O)C(c1ccccc1)(c2ccccc2)N3)COP(=O)(O)O
  • InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23) checkY
  • Key:XWLUWCNOOVRFPX-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Fosphenytoin, also known as fosphenytoin sodium, and sold under the brand name Cerebyx among others, is a water-soluble phenytoin prodrug that is administered intravenously to deliver phenytoin, potentially more safely than intravenous phenytoin. It is used in the acute treatment of convulsive status epilepticus.

Fosphenytoin was developed in 1996.[2] On 18 November 2004, Sicor (a subsidiary of Teva) received a tentative approval letter from the United States Food and Drug Administration for a generic version of fosphenytoin.[3]

  1. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
  2. ^ Pitkänen A, Schwartzkroin PA, Moshé SL (2005). Models of Seizures and Epilepsy. Burlington: Elsevier. p. 539. ISBN 9780080457024.
  3. ^ "Fosphenytoin Sodium Approval History". Retrieved 20 October 2005.

From Wikipedia, the free encyclopedia · View on Wikipedia

Developed by Nelliwinne